Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Revenue From Contracts With Customers (Tables)

v3.10.0.1
Note 4 - Revenue From Contracts With Customers (Tables)
9 Months Ended
Sep. 30, 2018
Notes Tables  
Disaggregation of Revenue [Table Text Block]
T
hree Months Ended
September
30
, 2018
 
Diagnostics
   
Therapeutics
   
Total
 
Tc99m tilmanocept royalty revenue:
                       
Europe
  $
2,382
    $
    $
2,382
 
India
   
     
     
 
China
   
     
     
 
Total
  $
2,382
    $
    $
2,382
 
                         
License revenue:
                       
NAV4694 sublicense
  $
14,930
    $
    $
14,930
 
Tc99m tilmanocept sublicense, China
   
5,000
     
     
5,000
 
Total
  $
19,930
    $
    $
19,930
 
                         
Other revenue:
                       
Additional stability studies
  $
    $
    $
 
Nine
Months Ended
Sep
t
ember
30, 2018
 
Diagnostics
   
Therapeutics
   
Total
 
Tc99m tilmanocept royalty revenue:
                       
Europe
  $
9,842
    $
    $
9,842
 
India
   
     
     
 
China
   
     
     
 
Total
  $
9,842
    $
    $
9,842
 
                         
License revenue:
                       
NAV4694 sublicense
  $
272,639
    $
    $
272,639
 
Tc99m tilmanocept sublicense, China
   
5,000
     
     
5,000
 
Total
  $
277,639
    $
    $
277,639
 
                         
Other revenue:
                       
Additional stability studies
  $
15,037
    $
    $
15,037
 
Contract with Customer, Asset and Liability [Table Text Block]
   
Three Months Ended
September
30,
   
Nine
Months Ended
September
30,
 
   
2018
   
2017
   
2018
   
2017
 
Total deferred revenue, beginning of period
  $
721,024
    $
26,061
    $
26,061
    $
41,098
 
Impact of adoption of ASU 2014-09 and related standards
   
     
     
700,000
     
 
Revenue deferred related to sublicense
   
     
     
10,000
     
 
Revenue recognized from satisfaction of performance obligations
   
(5,000
)
   
     
(20,037
)
   
(15,037
)
Total deferred revenue, end of period
  $
716,024
    $
26,061
    $
716,024
    $
26,061
 
Accounting Standards Update 2014-09 [Member]  
Notes Tables  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]
   
Pre-
Adoption
   
Post-
Adoption
   
Change
 
Deferred revenue
  $
26,061
    $
726,061
    $
700,000
 
Accumulated deficit
   
(319,908,968
)
   
(320,608,968
)
   
(700,000
)